Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection for prevention of radiotherapy-related adverse reactions in cervical cancer
ChiCTR-IPR-14005483Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection in Cervical Cancer (CC) (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoints: Incidence and degree of adverse reactions caused by radiotherapy, Rate of completing radiotherapy and 1 more. Started Oct 2014; status: recruiting.
02
Drugs
compound kushen injection
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005483.